Interim Analysis | The Truth About Skin Care

{ Tag Archives } Interim Analysis

Nitric BioTherapeutics Initiates Phase II Onychomycosis Study

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Dermatology; Clinical Trials / Drug Trials
Article Date: 16 Jul 2010 – 1:00 PDT

email to a friend printer friendly view / write opinions
<!– rate article

Nitric BioTherapeutics, Inc. (Nitric Bio) announced the initiation of a Phase II clinical trial of the [...]

Also tagged Biotherapeutics, Chairman Of The Board, Clinical Trial, Controlled Trial, Delivery System, Executive Chairman, Friendly View, Fungus, Industry Expert, Infectious Diseases, Iontophoresis, Onychomycosis, Oral Drug, Phase Ii, Quaker Bioventures, Rate Article, Skin And Nails, Terbinafine, Treatment Option

2010 07 16 Skin Care News Comments Off

Teva Comments On Positive Results Of Phase III Trial In MediWound’s Debrase(R)

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase®, an enzymatic debriding agent for burns.

Also tagged Burns, Nasdaq, Phase Iii, Teva Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd

2009 10 22 Skin Care News Comments Off

Glycotex’ Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based On Interim Analysis

Glycotex, Inc. announced the completion of a scheduled interim analysis in a Phase II study evaluating the effect of investigational GLYC-101 gel on complete wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area. The interim analysis was conducted after 26 subjects [...]

Also tagged Carbon Dioxide Laser, Carbon Dioxide Laser Skin Resurfacing, Cosmetic Outcomes, Cosmetic Surgery Patients, Glyc, Glycotex Inc, Investigational Compound, Laser Resurfacing, Laser Skin Resurfacing, Phase Ii, Wound Closure

2009 04 08 Skin Care News Comments Off

Galderma Announces Interim Data Relating To Sequential Treatment Regimen Of Clobex(R) Spray Followed By Vectical(TM) Ointment In Managing Psoriasis

Galderma Laboratories, L.P. announced interim findings from a study of sequential treatment of plaque psoriasis using Clobex(R) (clobetasol propionate) Spray 0.05% followed by treatment with Vectical(TM) (calcitriol) Ointment 3mcg/g. The results of an interim analysis of the data are to be presented in a poster session at the 67th Annual Meeting of the American Academy [...]

Also tagged Academy Of Dermatology, American Academy Of Dermatology, Annual Meeting, Clobetasol Propionate, Galderma Laboratories, Interim Data, Interim Findings, Plaque Psoriasis, Poster Session, Psoriasis, Reference Number, Treatment Regimen

2009 03 07 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Interim Analysis

Nitric BioTherapeutics Initiates Phase II Onychomycosis Study

Teva Comments On Positive Results Of Phase III Trial In MediWound’s Debrase(R)

Glycotex’ Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based On Interim Analysis

Galderma Announces Interim Data Relating To Sequential Treatment Regimen Of Clobex(R) Spray Followed By Vectical(TM) Ointment In Managing Psoriasis

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: